These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 1349746)

  • 1. Anxiolytic potential of 5-HT3 receptor antagonists.
    Costall B; Naylor RJ
    Pharmacol Toxicol; 1992 Mar; 70(3):157-62. PubMed ID: 1349746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The psychopharmacology of 5-HT3 receptors.
    Costall B; Naylor RJ; Tyers MB
    Pharmacol Ther; 1990; 47(2):181-202. PubMed ID: 2203069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Astra Award Lecture. The psychopharmacology of 5-HT3 receptors.
    Costall B; Naylor RJ
    Pharmacol Toxicol; 1992 Dec; 71(6):401-15. PubMed ID: 1362267
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The pharmacology of VA21B7: an atypical 5-HT3 receptor antagonist with anxiolytic-like properties in animal models.
    Artaiz I; Romero G; Zazpe A; Monge A; Calderó JM; Roca J; Lasheras B; Del Río J
    Psychopharmacology (Berl); 1995 Jan; 117(2):137-48. PubMed ID: 7753959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profile of action of 5-HT3 receptor antagonists, ondansetron and WAY 100289, in the elevated plus-maze test of anxiety of mice.
    Rodgers RJ; Cole JC; Tredwell JM
    Psychopharmacology (Berl); 1995 Feb; 117(3):306-12. PubMed ID: 7770606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. BRL 46470A: a highly potent, selective and long acting 5-HT3 receptor antagonist with anxiolytic-like properties.
    Blackburn TP; Baxter GS; Kennett GA; King FD; Piper DC; Sanger GJ; Thomas DR; Upton N; Wood MD
    Psychopharmacology (Berl); 1993; 110(3):257-64. PubMed ID: 7831418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serotonin and psychiatric disorders. A key to new therapeutic approaches.
    Costall B; Naylor RJ
    Arzneimittelforschung; 1992 Feb; 42(2A):246-9. PubMed ID: 1586395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-HT(3) receptor antagonists and anxiety; a preclinical and clinical review.
    Olivier B; van Wijngaarden I; Soudijn W
    Eur Neuropsychopharmacol; 2000 Mar; 10(2):77-95. PubMed ID: 10706989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profile of action of a novel 5-hydroxytryptamine1A receptor ligand E-4424 to inhibit aversive behavior in the mouse, rat and marmoset.
    Costall B; Domeney AM; Farre AJ; Kelly ME; Martinez L; Naylor RJ
    J Pharmacol Exp Ther; 1992 Jul; 262(1):90-8. PubMed ID: 1352556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of the 5-HT3 receptor antagonist, RS-42358-197, in animal models of anxiety.
    Costall B; Domeney AM; Kelly ME; Tomkins DM; Naylor RJ; Wong EH; Smith WL; Whiting RL; Eglen RM
    Eur J Pharmacol; 1993 Mar; 234(1):91-9. PubMed ID: 8097165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behavioural profiles in the mouse defence test battery suggest anxiolytic potential of 5-HT(1A) receptor antagonists.
    Griebel G; Rodgers RJ; Perrault G; Sanger DJ
    Psychopharmacology (Berl); 1999 May; 144(2):121-30. PubMed ID: 10394992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The anxiolytic-like effects of 5-hydroxytryptamine3 (5-HT3) receptor antagonists.
    Filip M; Baran L; Siwanowicz J; Chojnacka-Wójcik E; Przegaliński E
    Pol J Pharmacol Pharm; 1992; 44(3):261-9. PubMed ID: 1470564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of acute and chronic treatment of various serotonergic agents with those of diazepam and idazoxan in the rat elevated X-maze.
    Wright IK; Heaton M; Upton N; Marsden CA
    Psychopharmacology (Berl); 1992; 107(2-3):405-14. PubMed ID: 1352058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profiles of interaction of R(+)/S(-)-zacopride and anxiolytic agents in a mouse model.
    Barnes NM; Cheng CH; Costall B; Ge J; Kelly ME; Naylor RJ
    Eur J Pharmacol; 1992 Jul; 218(1):91-100. PubMed ID: 1356807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serotonergic innervation of the hippocampus and nucleus accumbens septi and the anxiolytic-like action of the 5-HT3 receptor antagonists.
    Stefański R; Pałejko W; Bidziński A; Kostowski W; Płaźnik A
    Neuropharmacology; 1993 Oct; 32(10):987-93. PubMed ID: 7905195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NMDA receptor complex antagonists have potential anxiolytic effects as measured with separation-induced ultrasonic vocalizations.
    Kehne JH; McCloskey TC; Baron BM; Chi EM; Harrison BL; Whitten JP; Palfreyman MG
    Eur J Pharmacol; 1991 Feb; 193(3):283-92. PubMed ID: 1675993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The enantiomers of zacopride: an intra-species comparison of their potencies in functional and anxiolytic models.
    Bill DJ; Coleman J; Hallett I; Middlefell VC; Rhodes KF; Fletcher A
    Br J Pharmacol; 1995 Jul; 115(5):775-80. PubMed ID: 8548176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antianxiety profile of ondansetron, a selective 5-HT3 antagonist, in a novel animal model.
    Roychoudhury M; Kulkarni SK
    Methods Find Exp Clin Pharmacol; 1997 Mar; 19(2):107-11. PubMed ID: 9151286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative study of the effects of selective and non-selective 5-HT2 receptor subtype antagonists in rat and mouse models of anxiety.
    Griebel G; Perrault G; Sanger DJ
    Neuropharmacology; 1997 Jun; 36(6):793-802. PubMed ID: 9225307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limbic mechanisms of anxiolytics acting on 5-HT receptors.
    Płaźnik A; Kostowski W; Stefański R
    Pol J Pharmacol; 1994; 46(5):473-7. PubMed ID: 7894537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.